CTOs on the Move

OmniSYS

www.omnisys.com

 
OmniSYS is a technology company with 25+ years of experience working with pharmacies, payers, providers and pharmaceutical manufacturers. We leverage this unique market insight along with our pharmacy workflow expertise to deliver valuable solutions that help pharmacies thrive in the changing pharmacy landscape. Our solutions help pharmacies engage patients, grow clinical services and improve financial performance. OmniSYS currently serves over 25,000 pharmacies, connects to hundreds of payers and touches millions of patient lives.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.omnisys.com
  • 15950 Dallas Parkway Suite 350
    Dallas, TX USA 75248
  • Phone: 214.459.2574

Executives

Name Title Contact Details

Similar Companies

Shawnee Mission Medical Center

Shawnee Mission Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Shawnee Mission Medical Center is based in Overland Park, KS. You can find more information on Shawnee Mission Medical Center at www.shawneemission.org

Jeffrey J Eckardt

Jeffrey J Eckardt is a Santa Monica, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Angels of Flight Canada

Angels of Flight Canada Inc. is a Peterborough, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bottom Line Benefits

Bottom Line Benefits is a Acworth, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cleveland Biolabs

Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an innovative bio pharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. We combine our proven scientific expertise and our depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our proprietary drug candidates act via unique mechanisms that are designed to kill cancer and protect healthy cells. Our most advanced product candidate is entolimod, which we are developing as a radiation countermeasure and an immunotherapy for oncology and other indications. We have additional pipeline product candidates in various stages of development.